Showing 6981-6990 of 8927 results for "".
- EZDERM Partners With Healthmonix to Provide Integrated MIPS Reporting for Dermatologistshttps://practicaldermatology.com/news/ezderm-partners-with-healthmonix-to-provide-integrated-mips-reporting-for-dermatologists/2458337/EZDERM, LLC and Healthmonix have partnered to integrate the MIPSPRO platform into the EZDERM suite of dermatology software solutions, including the integrated EZDERM Electronic Health Record and Practice Management systems. This partnership gives EZDERM clients access to education,
- Melanoma Incidence, Mortality On The Risehttps://practicaldermatology.com/news/melanoma-incidence-mortality-on-the-rise/2458339/Melanoma incidence and mortality is on the rise, according to a research letter published online by JAMA Dermatology. An estimated 76,380 Americans will be diagnosed with melanoma in 2016, and
- Dermavant Licenses Portola Pharma's Cerdulatinib For Skin Applicationshttps://practicaldermatology.com/news/dermavant-licenses-portola-pharmas-cerdulatinib-for-skin-applications/2458338/Dermavant Sciences has licensed cerdulatinib from Portola Pharma for topical dermatologic applications. Cerdulatinib is a dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor that Portola is developing to treat patients
- Oculus Innovative Sciences' SebuDerm Gel Availablehttps://practicaldermatology.com/news/fda-clears-oculus-innovative-sciences-sebuderm-gel/2458340/Oculus Innovative Sciences, Inc.’s Microcyn-based SebuDerm Gel is available in the US. As a prescription product, SebuDerm Gel is intended to manage and relieve the burning, itching, erythema, scaling, and pain experienced with seborrhea and seborrheic dermatitis. The gel, which
- Sandoz Acquires AmLactin Brandhttps://practicaldermatology.com/news/sandoz-acquires-amlactin-brand/2458342/Sandoz today announced that it has acquired the AmLactin® family of skin care brands from Minnesota-based pharmaceutical company Upsher-Smith Laboratories, Inc.
- FDA Approved Eucrisa (Crisaborole) for ADhttps://practicaldermatology.com/news/fda-approved-eucrisa-crisaborole-for-ad/2458344/The U.S. Food and Drug Administration approved Eucrisa (crisaborole) ointment to treat mild-to-moderate eczema in patients two years of age and older. Eucrisa, applied topically twice daily, is a phosphodiesterase 4 (PDE-4) i
- Points Group and Dermatology Authority Launch the Derm Toolkit: A Revolutionary Service and Product Line for Dermatology Practiceshttps://practicaldermatology.com/news/points-group-and-dermatology-authority-launch-the-derm-toolkit-a-revolutionary-service-and-product-line-for-dermatology-practices/2458346/Points Group and Dermatology Authority are excited to announce the launch of the Derm Toolkit, an online portal that provides dermatology practices with a comprehensive set of tools and services to operate more effectively and grow their practices. Over the next four months, the
- Study: Partner-Assisted Skin Self-Exams for Melanoma Don't Cause Embarrassmenthttps://practicaldermatology.com/news/study-partner-assisted-skin-self-exams-for-melanoma-dont-cause-embarrassment/2458345/Patients with melanoma may benefit from having their partners help to examine their skin for new skin cancers, and this does not cause embarrassment or discomfort for the patient or partner, finds a new study in
- Valeant Appoints William D. Humphries As EVP, Dermatologyhttps://practicaldermatology.com/news/valeant-appoints-william-d-humphries-as-evp-dermatology/2458348/Valeant Pharmaceuticals International, Inc. appointed William D. Humphries as Executive Vice President, Dermatology, effective January 2, 2017. Mr. Humphries will join Valeant's Executive Committee, reporting directly to
- Galderma's Restylane Refyne and Restylane Defyne Fillers FDA Approved for “Laugh Lines”https://practicaldermatology.com/news/galdermas-restylane-refyne-and-restylane-defyne-fillers-fda-approved-for-laugh-lines/2458349/The FDA approved two new products for the treatment of nasolabial folds (NLF) or “laugh lines,” in patients over the age of 21—Galderma's Restylane Refyne and Restylane Defyne. Restylane Refyne was approved for the treatment of moderate to severe facial wrinkl